SOAT1 and cancer: The activating mutations of JAK/STAT signaling or members of cellular biological process, inflammation, and immunity of cancer cells indicate that they are promising biomarkers for drug exploitation and malignancy treatment (Banerjee et al., 2017; Owen et al., 2019; Hin Tang et al., 2020).